Journal - Infectious Disorders - Drug Targets

Topic(s) Covered

5 Topic(s)

View

Aims & Scope

Infectious Disorders - Drug Targets aims to cover all the latest and outstanding developments in medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in infectious disorders e.g. disease specific proteins, receptors, enzymes and genes. Each issue of the journal contains a series of timely in-depth reviews/mini-reviews and research articles written by leaders in the field covering a range of current topics on drug targets involved in infectious disorders. As the discovery, identification, characterization and validation of novel human drug targets for anti-infective drug discovery continue to grow, this journal will be essential reading for all pharmaceutical scientists involved in drug design, discovery and development. All aspects related to viral or bacterial diseases including HIV, AIDS and other sexually transmitted diseases (STDs) are also included in the scope of the journal.

Abstracted & Indexed in:

BIOSIS Previews BIOSIS Reviews Reports and Meetings British Library Cabell's Directory/Journalytics Cambridge Scientific Abstracts (CSA)/ProQuest Chemical Abstracts Service/SciFinder CNKI Scholar EBSCO EMBASE ERA 2018 Genamics Journal Seek Google Scholar Index Copernicus Index Medicus J-Gate JournalTOCs MediaFinder®-Standard Periodical Directory MEDLINE/PubMed Norwegian Register OpenAire PubsHub QOAM Scilit Scopus Suweco CZ Ulrich's Periodicals Directory

Archiving and Copyright:

Portico Sherpa Romeo

Journal Database:

Dimensions

Special Offers

30% discount on the single-issue cost to authors on the purchase of issue(s) in which their article is published. Multiple issue copies at discounted rates.

COPE Compliant

Archived in

Endorsement(s)

"The rewards of genomics research translated into novel drug discovery using both traditional and innovative approaches will be captured in reviews of interest both to academic and applied infectious disease researches."

John Mekalanos
Harvard Medical School, USA